Capricor Awarded $2.4 Million by U.S. DoD to Develop Therapeutic Exosomes
Capricor Therapeutics, Inc. announced that the U.S. Department of Defense (DoD) has awarded the company a $2.4 million grant to establish a scalable, commercially-ready process to manufacture CAP-2003, the company’s proprietary exosome product candidate. Capricor is a clinical-stage biotechnology company working on the discovery, development and commercialization of biological therapies.